Current Report Filing (8-k)
October 08 2020 - 04:31PM
Edgar (US Regulatory)
false 0000876378 0000876378 2020-10-07
2020-10-07
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
_________________
FORM 8-K
_________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
October 7, 2020
Date of Report (date of earliest event reported)
_________________
TransEnterix, Inc.
(Exact name of Registrant as specified in its charter)
_________________
Delaware
(State or other jurisdiction of incorporation or
organization)
|
|
0-19437
(Commission
File Number)
|
|
11-2962080
(I.R.S. Employer
Identification Number)
|
635 Davis Drive, Suite 300
Morrisville, North Carolina 27560
(Address of principal executive offices)
919-765-8400
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last
report)
_________________
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐ Written communications pursuant to
Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
☐ Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading symbol
|
|
Name of each exchange on which registered
|
Common Stock
$0.001 par value per share
|
|
TRXC
|
|
NYSE American
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
☐
On October 7, 2020, TransEnterix, Inc., a Delaware corporation,
issued a press release to announce that Toshima Hospital of the
Tokyo Metropolitan Health and Hospitals
Corporation has entered into an agreement to lease and utilize
a Senhance® Surgical System.
A copy of the press release is filed herewith as Exhibit 99.1 and
incorporated herein by reference.
Item 9.01
|
Financial Statements and Exhibits.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
|
|
TRANSENTERIX, INC.
|
|
|
|
|
|
Date: October 8, 2020
|
|
/s/ Shameze Rampertab
|
|
|
|
Shameze Rampertab
|
|
|
|
Executive Vice President and Chief Financial Officer
|
|
2
TransEnterix (AMEX:TRXC)
Historical Stock Chart
From Dec 2020 to Jan 2021
TransEnterix (AMEX:TRXC)
Historical Stock Chart
From Jan 2020 to Jan 2021